Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Total Current Liabilities (2016 - 2026)

Cumberland Pharmaceuticals' Total Current Liabilities history spans 16 years, with the latest figure at $36.7 million for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 16.2% to $36.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $36.7 million, a 16.2% increase, with the full-year FY2025 number at $36.7 million, up 16.2% from a year prior.
  • Total Current Liabilities hit $36.7 million in Q4 2025 for Cumberland Pharmaceuticals, up from $24.3 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for CPIX hit a ceiling of $36.7 million in Q4 2025 and a floor of $17.9 million in Q3 2021.
  • Historically, Total Current Liabilities has averaged $25.7 million across 5 years, with a median of $25.4 million in 2022.
  • Biggest five-year swings in Total Current Liabilities: fell 25.03% in 2021 and later surged 48.24% in 2022.
  • Tracing CPIX's Total Current Liabilities over 5 years: stood at $19.3 million in 2021, then surged by 48.24% to $28.6 million in 2022, then fell by 2.09% to $28.0 million in 2023, then increased by 13.01% to $31.6 million in 2024, then rose by 16.2% to $36.7 million in 2025.
  • Business Quant data shows Total Current Liabilities for CPIX at $36.7 million in Q4 2025, $24.3 million in Q3 2025, and $24.0 million in Q2 2025.